A multicenter observational PMS study assessing Durvalumab safety in Indian adults with resectable NSCLC

Inclusion Criteria

• Inclusion Criteria:
• -
• 1. Patients with newly diagnosed previously untreated resectable NSCLC (tumors ≥ 4 cm and/or
• node positive) and no known EGFR mutations or ALK rearrangements prescribed with
• durvalumab as per local prescriber information.
• 2. Provision of signed, written and dated informed consent
• Exclusion Criteria:
• -
• 1. Presence of unresectable or metastatic disease.
• 2. Prior treatment with durvalumab for any other indications
• 3. Requires concurrent treatment for cancers other than resectable NSCLC
• 4. Concurrently participating in any other clinical trial
• 5. Patients with active or prior autoimmune disease or with medical conditions that required
• systemic corticosteroids or immunosuppressants
• 6. Any condition that, in the opinion of the investigator, would interfere with the patient’s
• participation in the study.